The Market Overreacted to the DEA's Marijuana Rescheduling -- Here's What It Means for Canopy Growth Stock Now

A long-awaited change in U.S. federal marijuana law occurred in late April, when the Drug Enforcement Administation rescheduled marijuana from its high-risk Schedule I to a Schedule III designation, which is for drugs with accepted medical use and low potential for dependence. The move was initially seen as a historic change for the drug and the industry that's grown up around it.However, the impact thus far has been relatively muted. Nevertheless, the reform will make a difference to certain cannabis companies. Let's look at how it might -- or, more appropriately, might not -- affect one of Canada's top marijuana companies, Canopy Growth (NASDAQ: CGC). Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool